Physician profile
Bashir A Chaudhary
NPI 1124072749
$4,622.02
in general payments reported to CMS, 2019-2025
24 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $669 · 2021: $364 · 2022: $601 · 2023: $984 · 2024: $563 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,268.29 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $567.39 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $493.45 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $388.92 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $296.53 | 2020-2025 | Wakix |
| Genzyme Corporation | $222.87 | 2023-2024 | |
| Axsome Therapeutics, INC. | $219.40 | 2022-2025 | Sunosi |
| Optinose US, INC. | $205.69 | 2019-2024 | |
| Kaleo, INC. | $185.99 | 2019-2023 | Auvi-Q |
| Amgen INC. | $128.90 | 2021-2023 | Tezspire |
| Resmed Corp | $117.85 | 2022-2025 | |
| Mylan Specialty L.P. | $109.39 | 2019-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $108.66 | 2019-2025 | |
| Grifols USA, LLC | $53.76 | 2024-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $42.79 | 2025 | Neffy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.44 | 2021-2022 | |
| Lilly USA, LLC | $40.29 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $37.69 | 2023-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $18.65 | 2025 | Lumryz |
| Pharming Healthcare, INC. | $17.88 | 2020 | |
| Genentech USA, INC. | $17.32 | 2019 | |
| Alk-Abello, INC | $15.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.27 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Chaudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.